News
ZTS
116.65
-1.04%
-1.22
Zoetis Price Target Cut to $130.00/Share From $136.00 by UBS
Dow Jones · 20h ago
Zoetis Is Maintained at Neutral by UBS
Dow Jones · 20h ago
UBS Maintains Neutral on Zoetis, Lowers Price Target to $130
Benzinga · 21h ago
Zoetis price target lowered to $130 from $136 at UBS
TipRanks · 22h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zoetis (ZTS) and Oruka Therapeutics (ORKA)
TipRanks · 23h ago
Analysts Offer Insights on Healthcare Companies: Zoetis (ZTS), Fulcrum Therapeutics (FULC) and Cormedix (CRMD)
TipRanks · 1d ago
Weekly Report: what happened at ZTS last week (0420-0424)?
Weekly Report · 2d ago
This Animal Health Stock Is Trading at Its Lowest P/E Ratio Ever
The Motley Fool · 3d ago
VanEck Agribusiness ETF Experiences Big Outflow
NASDAQ · 4d ago
Zoetis (ZTS) Valuation Check As Defensive Animal Health Leader Trades At A Discount
Simply Wall St · 4d ago
IDEXX Laboratories Vs. Zoetis: A Pre-Earnings Comparison
Seeking Alpha · 6d ago
Weekly Report: what happened at ZTS last week (0413-0417)?
Weekly Report · 04/20 09:14
Ex-Dividend Date Nearing for These 10 Stocks – Week of April 20, 2026
TipRanks · 04/20 08:50
The Week That Was, The Week Ahead: Macro and Markets, April 19
TipRanks · 04/19 08:23
How Investors Are Reacting To Zoetis (ZTS) Governance Stance Amid Optimistic Q1 2026 Earnings Expectations
Simply Wall St · 04/19 03:11
Assessing Zoetis (ZTS) Valuation After Citi’s Fresh Buy Rating And Osteoarthritis Drug Focus
Simply Wall St · 04/17 12:12
Ex-Div Reminder for Zoetis (ZTS)
NASDAQ · 04/16 14:36
What You Need To Know Ahead of Zoetis' Earnings Release
Barchart · 04/16 10:12
2 Healthcare Stocks to Buy and 1 to Approach With Caution
The Motley Fool · 04/15 21:20
Zoetis Initiated at Buy by Citigroup
Dow Jones · 04/15 18:31
More
Webull provides a variety of real-time ZTS stock news. You can receive the latest news about Zoetis Inc through multiple platforms. This information may help you make smarter investment decisions.
About ZTS
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).